Champions Oncology, Inc.

Informe Stock NasdaqCM:CSBR

Capitalización de mercado: US$68.0m

Salud financiera de hoja de balance de Champions Oncology

Salud financiera controles de criterios 1/6

Champions Oncology tiene unos fondos propios totales de $1.9M y una deuda total de $0.0, lo que sitúa su ratio deuda/fondos propios en 0%. Sus activos y pasivos totales son $29.9M y $28.0M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$4.47m
Patrimonio-US$2.06m
Total pasivoUS$28.85m
Activos totalesUS$26.79m

Actualizaciones recientes sobre salud financiera

Recent updates

Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Sep 28
Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M

Jul 21

We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

Oct 14
We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Jun 21
We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Apr 09
Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

Mar 19
Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Mar 02
The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Feb 04
Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Jan 14
Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Dec 19
Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares

Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Dec 16
Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results

Champions Oncology beats on revenue

Dec 14

Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Dec 04
Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Análisis de la situación financiera

Pasivos a corto plazo: CSBR tiene fondos propios negativos, que es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: CSBR tiene fondos propios negativos, lo que es una situación más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.


Historial y análisis de deuda-patrimonio

Nivel de deuda: CSBR está libre de deudas.

Reducción de la deuda: CSBR's tiene fondos propios negativos, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: CSBR tiene menos de un año de margen de liquidez basado en su flujo de caja libre actual.

Pronóstico de cash runway: CSBR tiene menos de un año de liquidez si el flujo de caja libre sigue reduciéndose al ritmo histórico de 4.2% cada año


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target